FDA Grants Fast Track Designation for Ambrx’s ARX517 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Ambrx Biopharma Inc. announced that the U.S. FDA has granted Fast Track designation to Ambrx’s proprietary anti-PSMA antibody-drug conjugate investigational therapy, ARX517, for the treatment of patients with metastatic castration-resistant prostate cancer.